Nonalcoholic steatohepatitis (NASH) is an aggressive form of nonalcoholic fatty liver disease (NAFLD), a liver condition that is characterized by liver steatosis accompanied by liver cell injury and inflammation.
Diagnosing the severity of NAFLD and NASH heavily relies on liver biopsy. While histological examination of the liver allows for precise diagnosis, it can cause abdominal discomfort and bleeding and may not be able to provide unbiased diagnosis if only a small section of hepatic tissue is analyzed. Because different components of liver pathology of NASH are characterized by distinct sets of protein signatures, non-invasive proteomic-based screening can now be used to detect these signatures and diagnose NASH.
Download this whitepaper to discover an assay that can:
- Identify biomarkers for susceptibility to NASH
- Reliably predict hepatic fat accumulation
- Help to predict the success of interventions in particular patient subpopulations